Production and characterization of thirteen human type-I interferon-α subtypes

Protein Expression and Purification

Volumn 103, Issue , 2014, Pages 75-83

  Kuruganti, Srilalitha ^a   Accavitti Loper, Mary Ann ^a   Walter, Mark R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Autoimmune disease; Interferon; Interferon subtype; Neutralizing antibodies; Protein purification

Indexed keywords

ALPHA INTERFERON; INTERFERON; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

BIOSYNTHESIS; ESCHERICHIA COLI; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ESCHERICHIA COLI; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA;

EID: 84908120539     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2014.08.010     Document Type: Article

References (40)

1. J.M. Gonzalez-Navajas et al., Immunomodulatory functions of type I interferons, Nat. Rev. Immunol. 12 (2) (2012) 125-135.
2. A. Isaacs, J. Lindenmann, Virus interference. I. The interferon, Proc. R. Soc. Lond. B Biol. Sci. 147 (927) (1957) 258-267.
3. S. Pestka, C.D. Krause, M.R. Walter, Interferons, interferon-like cytokines, and their receptors, Immunol. Rev. 202 (2004) 8-32.
4. G.R. Stark, How cells respond to interferons revisited: from early history to current complexity, Cytokine Growth Factor Rev. 18 (5-6) (2007) 419-423.
5. E.C. Borden et al., Interferons at age 50: past, current and future impact on biomedicine, Nat. Rev. Drug Discov. 6 (12) (2007) 975-990.
6. E. Baig, E.N. Fish, Distinct signature type I interferon responses are determined by the infecting virus and the target cell, Antivir. Ther. 13 (3) (2008) 409-422.
7. K. Gibbert, U. Dittmer, Distinct antiviral activities of IFN-alpha subtypes, Immunotherapy 3 (7) (2011) 813-816.
8. H.P. Moll et al., The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types, Cytokine 53 (1) (2011) 52-59.
9. S. Pestka, The interferons: 50 years after their discovery, there is much more to learn, J. Biol. Chem. 282 (28) (2007) 20047-20051.
10. S. Pestka, Purification and cloning of interferon alpha, Curr. Top. Microbiol. Immunol. 316 (2007) 23-37.
11. C. Robertson, et al., Methods and Uses of Antibodies in the Purification of Interferon, 2006, Google Patents.
12. L.E. Munoz-Espinosa et al., Re-treatment with highly purified nIFNalpha in Mexican nonresponder patients with chronic genotype 1 hepatitis C, Arch. Med. Res. 44 (6) (2013) 444-448.
13. E. Musch et al., Successful application of highly purified natural interferon alpha (multiferon) in a chronic hepatitis C patient resistant to preceding treatment approaches, Hepatogastroenterology 51 (59) (2004) 1476-1479.
14. T.B. Niewold et al., High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus, Genes Immun. 8 (6) (2007) 492-502.
15. J.S. Knight, M.J. Kaplan, Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis, Curr. Opin. Rheumatol. 24 (5) (2012) 441-450.
16. L. Ronnblom, G.V. Alm, M.L. Eloranta, The type I interferon system in the development of lupus, Semin. Immunol. 23 (2) (2011) 113-121.
17. M.K. Crow, Type I interferon in organ-targeted autoimmune and inflammatory diseases, Arthritis Res. Ther. 12 (Suppl. 1) (2010) S5.
18. F. Lefevre et al., Production, purification and biological properties of an Escherichia coli-derived recombinant porcine alpha interferon, J. Gen. Virol. 71 (Pt 5) (1990) 1057-1063.
19. E. Kalie et al., An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities, J. Biol. Chem. 282 (15) (2007) 11602-11611.
20. L. Shi et al., Efficient expression and purification of human interferon alpha2b in the methylotrophic yeast, Pichia pastoris, Protein Expr. Purif. 54 (2) (2007) 220-226.
21. S.A. Stifter et al., Purification and biological characterization of soluble, recombinant mouse IFNbeta expressed in insect cells, Protein Expr. Purif. 94 (2014) 7-14.
22. P. Srivastava et al., Overexpression and purification of recombinant human interferon alpha2b in Escherichia coli, Protein Expr. Purif. 41 (2) (2005) 313-322.
23. I. Rabhi-Essafi et al., A strategy for high-level expression of soluble and functional human interferon alpha as a GST-fusion protein in E. coli, Protein Eng. Des. Sel. 20 (5) (2007) 201-209.
24. B. Ruan et al., Engineering subtilisin into a fluoride-triggered processing protease useful for one-step protein purification, Biochemistry 43 (46) (2004) 14539-14546.
25. A. Deshpande et al., Kinetic analysis of cytokine-mediated receptor assembly using engineered FC heterodimers, Protein Sci. 22 (2013) 1100-1108.
26. M. Hussain, D.S. Gill, M.J. Liao, Identification of interferon-alpha 7, -alpha 14, and -alpha 21 variants in the genome of a large human population, J. Interferon Cytokine Res. 16 (10) (1996) 853-859.
27. M. Hussain, D.S. Gill, M.J. Liao, Both variant forms of interferon-alpha4 gene (IFNA4a and IFNA4b) are present in the human population, J. Interferon Cytokine Res. 17 (9) (1997) 559-566.
28. M. Hussain et al., Interferon-alpha 8b is the only variant of interferon-alpha 8 identified in a large human population, J. Interferon Cytokine Res. 16 (7) (1996) 523-529.
29. M. Hussain et al., A new allele of interferon-alpha17 gene encoding IFN-alpha17b is the major variant in human population, J. Interferon Cytokine Res. 18 (7) (1998) 469-477.
30. F.W. Studier, Protein production by auto-induction in high density shaking cultures, Protein Expr. Purif. 41 (1) (2005) 207-234.
31. G. Uze et al., Domains of interaction between alpha interferon and its receptor components, J. Mol. Biol. 243 (2) (1994) 245-257.
32. A. Meister et al., Biological activities and receptor binding of two human recombinant interferons and their hybrids, J. Gen. Virol. 67 (Pt 8) (1986) 1633-1643.
33. A. Meager et al., Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega, J. Immunol. Methods 257 (1-2) (2001) 17-33.
34. D. Platis, G.R. Foster, High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coli, Protein Expr. Purif. 31 (2) (2003) 222-230.
35. H. Schmeisser et al., Binding characteristics of IFN-alpha subvariants to IFNAR2-EC and influence of the 6-histidine tag, J. Interferon Cytokine Res. 26 (12) (2006) 866-876.
36. J. Piehler, G. Schreiber, Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2, J. Mol. Biol. 289 (1) (1999) 57-67.
37. H.P. Moll et al., Contamination with recombinant IFN accounts for the unexpected stimulatory properties of commonly used IFN-blocking antibodies, Eur. J. Immunol. 41 (1) (2011) 252-254.
38. H.P. Moll et al., Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells, J. Immunol. 180 (8) (2008) 5250-5256.
39. T.B. Lavoie et al., Binding and activity of all human alpha interferon subtypes, Cytokine 56 (2) (2011) 282-289.
40. S. Ouyang et al., Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus, J. Mol. Med. (Berl.) 90 (7) (2012) 837-846.